Abstract
Elevated cerebrospinal fluid concentrations of tau discriminate Alzheimer's disease from other neurodegenerative conditions. The reasons for this are unclear. While commercial assay kits are widely used to determine total-tau concentrations, little is known about their ability to detect different aggregation states of tau. We demonstrate that the leading commercial enzyme-linked immunosorbent assay reliably detects aggregated and monomeric tau and evinces good recovery of both species when added into cerebrospinal fluid. Hence, the disparity between total-tau levels encountered in Alzheimer's disease and other neurodegenerative conditions is not due to differential recognition of tau assembly forms or the extent of degeneration.
Original language | English |
---|---|
Pages (from-to) | 923-928 |
Number of pages | 6 |
Journal | Journal of Alzheimer's Disease |
Volume | 33 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2013 |
Externally published | Yes |
Keywords
- Alzheimer's disease
- ELISA
- cerebrospinal fluid
- tau
ASJC Scopus subject areas
- General Neuroscience
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health